A study to evaluate the safety of platelet-derived growth factor for treatment of XXXX of the talus.

@entity1 @entity4713 @entity9039 @entity3681 @entity4 @entity158
PURPOSE: An arthroscopic procedure for the treatment of @entity4713 using platelet-derived growth factor (PDGF) carried out in a matrix of @entity9039 was developed. This prospective, case-series-based study was designed to evaluate the safety and clinical utility of this procedure. METHODS: @entity1 with an isolated @entity4713 larger than 5  mm long, 3  mm wide, and 5  mm deep and smaller than 30  mm long, 25  mm wide, or 20  mm deep were considered for enrolment. Only @entity1 with chronic lesions were enroled. Arthroscopic debridement was followed by the placement of recombinant @entity1 PDGF in a matrix of @entity9039 . The @entity3681 ( @entity3681 ), visual analogue scale (VAS) for @entity158 , and SF-36 questionnaires were administered at 0, 2, 6, 12, and 24  weeks. Magnetic resonance imaging (MRI) and computed tomography (CT) scans were taken before and after surgery. RESULTS: Five @entity1 were ultimately enroled in this proof-of-concept trial. All outcome measures demonstrated marked improvement from baseline to final follow-up: The mean weight bearing VAS @entity158 score improved by 49  %, and the mean @entity3681 functional score improved by 28  %. Bone healing was seen on CT, and reduction in @entity4 signal was seen on MRI. CONCLUSION: This new procedure may offer a promising alternative for the treatment of @entity4713 . Further high-quality studies are needed to confirm these results and to analyse the long-term effects of the procedure. The clinical relevance of this study is that the procedure may provide a less invasive option with improved bone healing compared to standard techniques . LEVEL OF EVIDENCE: IV.
